Modeling the Cost-Effectiveness of Novel Direct Acting Antiviral (DAA) Treatments In Patients Co-Infected with Hepatitis C Virus (Hcv) and Human Immunodeficiency Virus (HIV)

May 1, 2015, 00:00
10.1016/j.jval.2015.03.1391
https://www.valueinhealthjournal.com/article/S1098-3015(15)01448-5/fulltext
Title : Modeling the Cost-Effectiveness of Novel Direct Acting Antiviral (DAA) Treatments In Patients Co-Infected with Hepatitis C Virus (Hcv) and Human Immunodeficiency Virus (HIV)
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01448-5&doi=10.1016/j.jval.2015.03.1391
First page : A239
Section Title : Infection
Open access? : No
Section Order : 855
Categories :
Tags :
Regions :
ViH Article Tags :